Point72 Asia Singapore Pte. Ltd. Sells 3,756 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Point72 Asia Singapore Pte. Ltd. lessened its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 83.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 746 shares of the company’s stock after selling 3,756 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Amphastar Pharmaceuticals were worth $30,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of AMPH. YHB Investment Advisors Inc. bought a new position in Amphastar Pharmaceuticals in the 1st quarter worth approximately $27,000. Innealta Capital LLC bought a new position in Amphastar Pharmaceuticals in the 2nd quarter worth approximately $55,000. Blue Trust Inc. raised its position in Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares during the last quarter. nVerses Capital LLC raised its position in Amphastar Pharmaceuticals by 37.5% in the 2nd quarter. nVerses Capital LLC now owns 2,200 shares of the company’s stock worth $88,000 after purchasing an additional 600 shares during the last quarter. Finally, 1620 Investment Advisors Inc. bought a new position in Amphastar Pharmaceuticals in the 2nd quarter worth approximately $93,000. Institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

AMPH has been the subject of several research analyst reports. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $63.00.

Amphastar Pharmaceuticals Stock Performance

Shares of Amphastar Pharmaceuticals stock opened at $48.35 on Wednesday. The firm has a fifty day moving average of $45.55 and a two-hundred day moving average of $42.75. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of 16.73, a PEG ratio of 0.92 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The company had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. As a group, equities research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current year.

Insider Activity

In other news, CFO William J. Peters sold 10,282 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the transaction, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $4,162,175.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CFO William J. Peters sold 10,282 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the transaction, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $4,162,175.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the transaction, the director now directly owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The disclosure for this sale can be found here. Insiders sold 34,383 shares of company stock valued at $1,524,123 in the last quarter. Company insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.